Truly an honor to give the #Keynote Lecture @columbiacancer on Targeting #KRAS in #PancreaticCancer: G12C, RASON, GDP inhibitors, PROTAC, vaccines and much more!!! 🙏🙏 @DrGManji and faculty for the kind invite and congratulations on a fantastic symposium!!!

Happy to report that our trial in gastric cancer published in JAMAOnc. Privileged to have worked with ⁦@mdmanishshah⁩, ⁦@ParkHaesong⁩, and AlexRaufi. Thanks to all the patients who participated in the study.

Proud to report the results of the pilot phase of our investigator-initiated clinical trial @AACR Pancreas. I started the preclinical study in KPC mice in @KenOliveLab and then work continued in my lab. Randomized phase 2 to activate soon at 5 sites!

On the latest episode of Columbia Conversations & Curbsides, Dr. Gulam Manji (@DrGManji) sits down to share updates on the current state of pancreatic cancer care. @ColumbiaSurgery Listen here:

Oncologist and director of medical oncology and translational #PanCan research, @DrGManji joined @hyesooLoweMD to discuss the past, present, and future of pancreatic cancer—from genetic mutations to clinical-trial awareness and personalized treatment:

Thank you for the discussion, @hyesooLoweMD. It brings much needed attention to pancreatic cancer and highlights the need for more patients to enroll in clinical trials. #PanCan

Comprehensive discussion by @LizzySmyth1 of the phase II trial by Dr. Gulam Manji et al➡️ peri-operative chemotherapy/pembrolizumab in resectable gastric/OGJ adenoca followed by adjuvant pembro. Proof of principle of increased RR; phase 3 data awaited @AACR #AACR22.

Thanks @KenOliveLab for the warm welcome to Twitter! Finally joining in to highlight the great work being done in GI immuno-oncology